open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23
Get Citation

Second line erlotinib therapy in a non-smoking patient with metastatic non-small-cel lung cancer harbouring EGFR mutation

Marta Skoczek, Grzegorz Czyżewicz

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-23

Abstract

The majority of non small cel lung cancer (NSCLC) patients are diagnosed with locally advanced or metastatic disease. Randomised trials have shown that in a selected group of patients with advanced NSCLC, molecularly targeted therapies prolong the progression-free survival time compared to chemotherapy, with favorable toxicity profile and patients’ better quality of life. Gefitinib and erlotinib — small molecule tyrosine kinase inhibitors (TKI) of epidermal growth factor receptor (EGFR) can be used in clinical practice in the first line treatment of patients with metastatic NSCLC with activating mutation in the EGFR gene, and after failure of at least one prior chemotherapy regimen. We present a case of erlotinib therapy in non-smoking patient diagnosed with metastatic NSCLC with EGFR activating mutation, after first-line palliative chemotherapy failure.

Abstract

The majority of non small cel lung cancer (NSCLC) patients are diagnosed with locally advanced or metastatic disease. Randomised trials have shown that in a selected group of patients with advanced NSCLC, molecularly targeted therapies prolong the progression-free survival time compared to chemotherapy, with favorable toxicity profile and patients’ better quality of life. Gefitinib and erlotinib — small molecule tyrosine kinase inhibitors (TKI) of epidermal growth factor receptor (EGFR) can be used in clinical practice in the first line treatment of patients with metastatic NSCLC with activating mutation in the EGFR gene, and after failure of at least one prior chemotherapy regimen. We present a case of erlotinib therapy in non-smoking patient diagnosed with metastatic NSCLC with EGFR activating mutation, after first-line palliative chemotherapy failure.

Get Citation

Keywords

nonsmall cell lung cancer, molecularly targeted therapy, erlotinib, EGFR activating mutations

About this article
Title

Second line erlotinib therapy in a non-smoking patient with metastatic non-small-cel lung cancer harbouring EGFR mutation

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

56-60

Published online

2015-03-23

Keywords

nonsmall cell lung cancer
molecularly targeted therapy
erlotinib
EGFR activating mutations

Authors

Marta Skoczek
Grzegorz Czyżewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl